US3755581036 - Common Stock

Taking everything into account, **GILD** scores **6** out of 10 in our fundamental rating. **GILD** was compared to 577 industry peers in the **Biotechnology** industry. **GILD** scores excellent on profitability, but there are some minor concerns on its financial health. **GILD** has a bad growth rate and is valued cheaply.

In the past year **GILD** was profitable.

In the past year **GILD** had a positive cash flow from operations.

In the past 5 years **GILD** always reported a positive cash flow from operatings.

Looking at the **Return On Equity**, with a value of **2.76%**, **GILD** belongs to the top of the industry, outperforming **94.77%** of the companies in the same industry.

The **Return On Invested Capital** of **GILD** (**17.16%**) is better than **97.74%** of its industry peers.

Measured over the past 3 years, the **Average Return On Invested Capital** for **GILD** is in line with the industry average of **14.68%**.

The last **Return On Invested Capital** (**17.16%**) for **GILD** is above the 3 year average (**14.77%**), which is a sign of increasing profitability.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 0.86% | ||

ROE | 2.76% | ||

ROIC | 17.16% |

ROA(3y)8.52%

ROA(5y)6.89%

ROE(3y)25.33%

ROE(5y)20.11%

ROIC(3y)14.77%

ROIC(5y)11.39%

In the last couple of years the **Profit Margin** of **GILD** has declined.

In the last couple of years the **Operating Margin** of **GILD** has declined.

In the last couple of years the **Gross Margin** of **GILD** has remained more or less at the same level.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 33.73% | ||

PM (TTM) | 1.76% | ||

GM | 77.52% |

OM growth 3Y27.82%

OM growth 5Y-1.87%

PM growth 3Y247.42%

PM growth 5Y-3.26%

GM growth 3Y-1.53%

GM growth 5Y-0.07%

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so **GILD** is still creating some value.

Compared to 1 year ago, **GILD** has about the same amount of shares outstanding.

The debt/assets ratio for **GILD** is higher compared to a year ago.

An Altman-Z score of **2.72** indicates that **GILD** is not a great score, but indicates only limited risk for bankruptcy at the moment.

Looking at the **Altman-Z score**, with a value of **2.72**, **GILD** is in the better half of the industry, outperforming **73.87%** of the companies in the same industry.

The Debt to FCF ratio of **GILD** is **3.19**, which is a good value as it means it would take **GILD**, **3.19** years of fcf income to pay off all of its debts.

The **Debt to Equity ratio** of **GILD** (**1.23**) is worse than **78.92%** of its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 1.23 | ||

Debt/FCF | 3.19 | ||

Altman-Z | 2.72 |

ROIC/WACC1.7

WACC10.09%

A Current Ratio of **1.08** indicates that **GILD** should not have too much problems paying its short term obligations.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1.08 | ||

Quick Ratio | 0.94 |

The earnings per share for **GILD** have decreased strongly by **-33.28%** in the last year.

Measured over the past 5 years, **GILD** shows a small growth in **Earnings Per Share**. The EPS has been growing by **1.09%** on average per year.

Looking at the last year, **GILD** shows a small growth in **Revenue**. The Revenue has grown by **1.51%** in the last year.

Measured over the past years, **GILD** shows a small growth in **Revenue**. The Revenue has been growing by **4.15%** on average per year.

EPS 1Y (TTM)-33.28%

EPS 3Y-0.24%

EPS 5Y1.09%

EPS Q2Q%-196.35%

Revenue 1Y (TTM)1.51%

Revenue growth 3Y3.17%

Revenue growth 5Y4.15%

Sales Q2Q%5.26%

Based on estimates for the next years, **GILD** will show a small growth in **Earnings Per Share**. The EPS will grow by **3.70%** on average per year.

Based on estimates for the next years, **GILD** will show a small growth in **Revenue**. The Revenue will grow by **2.35%** on average per year.

EPS Next Y-45.6%

EPS Next 2Y1.84%

EPS Next 3Y3.22%

EPS Next 5Y3.7%

Revenue Next Year1.82%

Revenue Next 2Y1.54%

Revenue Next 3Y2.01%

Revenue Next 5Y2.35%

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

With a **Price/Earnings** ratio of **16.65**, **GILD** is valued correctly.

Based on the **Price/Earnings** ratio, **GILD** is valued cheaply inside the industry as 97.74% of the companies are valued more expensively.

The average S&P500 **Price/Earnings** ratio is at **29.08**. **GILD** is valued slightly cheaper when compared to this.

With a **Price/Forward Earnings** ratio of **9.92**, the valuation of **GILD** can be described as very reasonable.

Based on the **Price/Forward Earnings** ratio, **GILD** is valued cheaply inside the industry as 98.08% of the companies are valued more expensively.

The average S&P500 **Price/Forward Earnings** ratio is at **20.74**. **GILD** is valued rather cheaply when compared to this.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 16.65 | ||

Fwd PE | 9.92 |

Based on the **Enterprise Value to EBITDA** ratio, **GILD** is valued cheaply inside the industry as 98.08% of the companies are valued more expensively.

99.30% of the companies in the same industry are more expensive than **GILD**, based on the **Price/Free Cash Flow** ratio.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 11.42 | ||

EV/EBITDA | 9.24 |

The excellent profitability rating of **GILD** may justify a higher PE ratio.

PEG (NY)N/A

PEG (5Y)15.33

EPS Next 2Y1.84%

EPS Next 3Y3.22%

Compared to an average S&P500 **Dividend Yield** of **2.29**, **GILD** pays a better dividend.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 4.19% |

The dividend of **GILD** has a limited annual growth rate of **5.90%**.

As **GILD** did not decrease their dividend in the past **5** years, we can say the dividend looks stable.

Dividend Growth(5Y)5.9%

Div Incr Years8

Div Non Decr Years8

The dividend of **GILD** is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.

DP791.32%

EPS Next 2Y1.84%

EPS Next 3Y3.22%

**GILEAD SCIENCES INC**

NASDAQ:GILD (7/22/2024, 7:25:56 PM)

After market: 72.41 0 (0%)**72.41**

**-0.15 (-0.21%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap90.21B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 4.19% |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 16.65 | ||

Fwd PE | 9.92 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)15.33

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 0.86% | ||

ROE | 2.76% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 33.73% | ||

PM (TTM) | 1.76% | ||

GM | 77.52% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.49

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 1.23 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 1.08 | ||

Quick Ratio | 0.94 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-33.28%

EPS 3Y-0.24%

EPS 5Y

EPS Q2Q%

EPS Next Y-45.6%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)1.51%

Revenue growth 3Y3.17%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y